Which cancer drugs don’t work for a patient?
Consider this scenario: A patient has a solid tumor that lacks easy-to-target biomarkers.
Because each person’s cancer is unique and responds differently to treatments, a physician is torn between multiple options without knowing which one is the best:
“Should I use immunotherapy? Or chemotherapy? Would an antibody-drug conjugate be the best? Or should I use a combination therapy?”
Deciding on a treatment can sometimes feel like playing Russian roulette. Maybe the treatment works. Maybe the patient condition stays the same - or becomes even worse.
To maximize the chance of survival for each patient, we test FDA-approved drugs, including combination therapies, on patient tumor samples to predict drug response. That way, we can flag and eliminate the ineffective treatments so that the physician has fewer but more effective options.
We are in the early feasibility phase of gathering clinical validation, so our device is currently for research use only.